News | February 03, 2009

Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent

February 2, 2009 - Boston Scientific Corp. today said it began patient enrollment in the PLATINUM clinical trial, which is designed to evaluate the company’s PROMUS Element Everolimus-Eluting Coronary Stent.

The first U.S. patient was enrolled last week at the Medical Center of the Rockies in Loveland, Colorado by Thomas Downes, M.D. The first Japanese patient was also enrolled last week.

The PLATINUM clinical program will enroll 1,728 patients at 160 sites worldwide. The trial will compare the PROMUS Element Everolimus-Eluting Coronary Stent to the PROMUS Everolimus-Eluting Coronary Stent. The company plans to develop additional variations of the Element Stent platform, including next generations of a bare-metal stent and a paclitaxel-eluting TAXUS Element Stent.

The Element Stent platform features a proprietary Platinum Chromium Alloy, designed specifically for coronary stents. This alloy, coupled with new stent architecture, is designed to enable thinner struts, increased flexibility and a lower profile while improving radial strength, recoil and visibility. In addition, the PROMUS Element Stent System incorporates the new Apex Dilatation Catheter technology, designed to enhance deliverability to complex lesions.

The global principal investigator for the trial is Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation in New York. The U.S. co-principal investigator is Paul Teirstein, M.D., of Scripps Green Hospital in La Jolla, California, and the international co-principal investigator is Ian Meredith, M.D., Ph.D., director of cardiology at the Monash Medical Centre in Melbourne, Australia.

“The new alloy and stent design of the PROMUS Element Stent promise to offer improved deliverability and visibility, even in patients with complex and challenging anatomy,” said Dr. Stone. "I am enthusiastic about the possibility of having both everolimus and paclitaxel versions of this innovative stent system available, allowing for the tailored treatment of patients with coronary artery disease."

The PLATINUM clinical program will evaluate the safety and efficacy of the PROMUS Element Stent in three studies. The first, PROMUS PLATINUM Workhorse, will evaluate the safety and efficacy of the PROMUS Element Stent compared to Boston Scientific's PROMUS Stent. This 1:1 randomized study will evaluate 1,532 patients from 160 global sites with de novo "workhorse" lesions from 2.5 to 4.25 mm in diameter and less than 24 mm in length. The primary endpoint of the workhorse study is target lesion failure (TLF) at 12 months, with clinical follow-up scheduled out to five years.

Two additional parallel studies will evaluate the PROMUS Element Stent in small vessels and long lesions. The small vessel study will examine lesions from 2.25 to 2.5 mm in diameter and less than or equal to 28 mm in length, while the long lesion study will examine lesions from 2.5 to 4.25 mm in diameter and 24 to 34 mm in length. The primary endpoint of both studies is TLF at 12 months.

For more information: www.bostonscientific.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init